 CAMBRIDGE, Mass.--BUSINESS WIRE--Gemini Therapeutics, Inc. Nasdaq: GMTX, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration AMD and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference on Thursday, February 25 at 1:00 PM ET. A live webcast of the event wi 